ArticleKidney medicine2025
Comparison of the 2021 and 2012 CKD-EPI eGFR Equations With the 2009 CKD-EPI eGFR Equation in a Chinese Population.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Population pharmacokinetic model of high-dose methotrexate in Malaysian adults with hematological malignancies.European journal of clinical pharmacology · 2026Article
- Association of Serum Uric Acid With Cardiovascular-Kidney-Metabolic Risk in a Rural Indian Population.JACC. Asia · 2026Article
- Diagnostic value of tubular and glomerular biomarkers across different stages of kidney injury in patients with type 2 diabetic nephropathy.Frontiers in endocrinology · 2026Observational
- The creatinine-to-cystatin C ratio as a prognostic risk-stratification biomarker in chronic kidney disease.Frontiers in nutrition · 2026Article
- Impact of Estimated Glomerular Filtration Rate Equations on Vancomycin Dosing and Treatment Outcomes.Drug design, development and therapy · 2026Article
- Effect of traumatic brain injury on the trough concentration of linezolid in patients with hospital-acquired pneumonia.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: The 2024 KDIGO guideline recommends the use of the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. We used the most widely applied 2009 CKD-EPI estimated glomerular filtration rate based on creatinine (eGFRcr) equation as a reference to compare the other 4 CKD-EPI eGFR equations in a large clinical population in China. Study Design: A cross-sectional analysis. Setting & Participants: Individuals with clinical encounters at Zhongshan Hospital, Fudan University, from July 1, 2017, to July 1, 2023, who had both creatinine (cr) and cystatin C (cys) tested. Exposures: Serum cr and serum cys. Outcomes: This study compared the clinical effects of the 2012 CKD-EPI eGFR cr-cys and eGFRcys, 2021 CKD-EPI eGFRcr and eGFRcr-cys according to the 2009 CKD-EPI eGFRcr in a large clinical population in China. Analytical Approach: The eGFR results were statistically evaluated according to sex, age, serum cys, and serum cr levels, and CKD stage. Results: The 2009 CKD-EPI eGFRcr had the overall result with a median of 74.9 mL/min/1.73m Limitations: Lack of measured GFR. Conclusions: The 2021 and the 2009 CKD-EPI eGFRcr results appeared to have the best comparability, whereas the results of the 2012 CKD-EPI eGFRcys and the 2009 CKD-EPI eGFRcr showed the most obvious difference. The differences between eGFR equations should be considered when judging the CKD stage of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.